There's an Update on Security for Biden's Gaza Port and a New 'Peacekeeping...
Biden Blows Off Respects for Murdered New York City Police Officer
New York City Councilwoman Gets Ratioed Into Oblivion Over One Question
Sam Bankman-Fried Sentenced in Massive Crypto Fraud Case
‘No Tampons, No Peace!’: Panic at Vanderbilt University Sit-In As Protestors Realize It...
Charlotte Radio Host Speaks Out About His Interview With KJP That Made Headlines
Trump, Biden Will Both Be in New York on Thursday...but for Very Different...
New Poll Shows How Hispanic Voters Feel About Biden Describing Laken Riley's Alleged...
Who Will Replace Mike Gallagher? Poll Shows It's Pro-Trump Alex Bruesewitz’s 'Race to...
Flashback: Two Cycles After Running on Gore's Ticket, Lieberman Endorses McCain at GOP...
Here's When Impeachment Articles Against Mayorkas Will Be Presented to the Senate
Tennessee Music Venue to Host ‘Trans Day Of Vengeance’ Event One Year After...
There Was Very Little Pete Buttigieg Was Able to Tell Us About Bridge...
An Illegal Alien Encouraged Others to Invade American Homes. Here's What Happened Next.
Time for Another Bizarre, Easily-Disprovable Lie From Joe Biden
Tipsheet

Taxpayers Were The Largest Purchaser of EpiPens Last Year

Perhaps this is the reason the price of lifesaving EpiPens increased so dramatically: the single-largest purchaser of the pens in 2015 were taxpayers.

The largest source of Mylan's increased revenue came from increased spending from Medicaid and Medicare for the devices. The price of the EpiPens has increased by over 400 percent since Medicaid and Medicare became a larger percentage of EpiPen's revenue.

Advertisement

"The majority of Mylan's EpiPen revenue growth came from Medicare and Medicaid," Senator Chuck Grassley told NBC News in a statement after the Iowa Republican's office published an analysis of newly released data on rebates paid by the drugmaker to the government.

The two programs, which help cover healthcare costs for the poor and elderly, are funded by taxpayer dollars.

From 2011 to 2015, government spending rose from being 23 percent of Mylan's EpiPen revenue to 53 percent, according to Grassley's analysis of Centers for Medicare and Medicaid Services (CMS) figures disclosed this week.

At the same time, the price the government paid for the emergency allergic reaction treatment rose by 463 percent.

Curious.

Obviously a company has no qualms with increasing (and over-charging) the price of something when the government is willing to buy a large quantity. Private consumers, however, are the ones getting screwed.

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos

Advertisement
Advertisement
Advertisement